- Lexaria’s fast-acting, high absorption technology will improve dipping experience and consumer satisfaction
- Partnership will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery platform to Cannadips Cannnabis products in California and nationwide
- Cannadips to open one-of-a-kind cannabis oral pouch and dip research facility
Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use on the latter’s market in California and nationwide according to a new definitive agreement. Currently, Cannadips Cannabis Tins are sold in California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol each, no nicotine, no tobacco, and all-natural sweeteners. The company also has a high-dose version with 15 pouches and 20 mg of cannabis-derived THC each (http://ibn.fm/N0pdA).
Lexaria’s DehydraTECH(TM) drug delivery platform is perfectly suited to improve the dipping experience through its effective, high absorption technology. Cannadips uses multi spectrum oils as base ingredients. The oils are rich in high-quality terpenes, which ensure the much-coveted entourage effect. DehydraTECH(TM) minimizes the throat irritation usually associated with some terpenes.
“Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,” Chris Bunka, CEO of Lexaria Bioscience Corp., stated in a news release. “Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets.”
The licensing agreement provided by Lexaria grants Cannadips exclusive rights for this product format for the U.S. market for 10 years, with the option to expand the license to Canada, Mexico and/or Europe.
According to Case Mandel, co-founder and chief executive officer of Cannadips Cannabis, the agreement will allow Cannadips to partner with operators in other states and bring its cannabis technology across state lines. “Our cannabis oral pouch and dip research facility in Humboldt is going to be the first of its kind in our brand new 4,000 square foot facility. We are also highly interested in activating the Canadian Oral Pouch Cannabinoid market,” Mandel added. Cannadips’ new 4,000 square foot oral cannabinoid research and development facility in Arcata, California will house manufacturing, corporate offices, distribution, and retail.
Lexaria Bioscience has launched a revolutionary technology that accelerates intestinal absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sweeteners or sugars, and other unhealthy practices. It is applicable to absorption of cannabis and nicotine, among other bioactive substances (http://ibn.fm/GdBAc). The DehydraTECH(TM) drug delivery platform is patented for all non-psychoactive cannabinoids as well as for tetrahydrocannabinol and psychoactive cannabinoids. The platform reduces the time of onset of THC by four times on average (http://ibn.fm/DHOzB).
Lexaria is the leading company in the world that holds patents for oral delivery of all cannabinoids. The company holds 60 globally pending patents. Recently, Lexaria obtained two patents for treating certain conditions including, but not limited to, heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia and others. The technology has potential applications to assist treatment of the common form of dementia as well as other nervous system diseases.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP